FAM160A1

Across TCGA pan-cancer cohorts, FAM160A1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM160A1 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher FAM160A1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM160A1 expression acts as an unfavorable survival marker.

SARC, ACC, and UCEC are the cancer types where FAM160A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.053	0.616	<.001	12	view →
ACC	DFS	Median	All	0.068	0.667	.005	12	view →
UCEC	OS	Median	IV	0.277	0.605	.013	6	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM160A1–SARC (DFS)

Open the SARC breakdown →